- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.06. | Meihua International wechselt zum Nasdaq Capital Market für Compliance | - | Investing.com Deutsch | ||
| 06.06. | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.04. | Meihua GAAP EPS of $0.40, revenue of $96.91M | 1 | Seeking Alpha | ||
| 25.04. | Meihua International Medical Technologies Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 25.04. | Meihua International Medical Technologies Co., Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.04. | Meihua International Medical Technologies Co., Ltd. Full Year Income Retreats | 275 | AFX News | BEIJING (dpa-AFX) - Meihua International Medical Technologies Co., Ltd. (MHUA) released a profit for full year that decreased from the same period last yearThe company's bottom line came in... ► Artikel lesen | |
| 25.04. | Meihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year Results | 130 | PR Newswire | YANGZHOU, China, April 25, 2025 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer... ► Artikel lesen | |
| 20.09.24 | Meihua International Medical Technologies Co., Ltd.: Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results | 265 | PR Newswire | YANGZHOU, China, Sept. 20, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,118 | +0,85 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,641 | +0,63 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required
Strong... ► Artikel lesen | |
| PING AN HEALTHCARE | 1,732 | +1,64 % | Ping An Healthcare and Technology Company Limited: Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth | HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,011 | -13,64 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| CO-DIAGNOSTICS | 0,254 | +4,96 % | Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results | SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
| CYTOSORBENTS | 0,790 | +0,89 % | CytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR | FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization... ► Artikel lesen | |
| VERU | 3,550 | +9,57 % | Veru Announces Novel Modified-Release Oral Formulation for Enobosarm | ||
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
| VOLITIONRX | 0,675 | 0,00 % | VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2025 /PRNewswire/ -- VolitionRx... ► Artikel lesen | |
| EKSO BIONICS | 3,275 | +5,65 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| IMUNON | 5,210 | -5,96 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
| BEYOND AIR | 2,120 | 0,00 % | Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Japan | GARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| NOVACYT | 0,479 | +2,24 % | Novacyt S.A. - Liquidity Agreement Monthly Update & TVR | ||
| AROVELLA THERAPEUTICS | 0,043 | -4,44 % | XFRA E4NA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO LTD gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,400 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO LTD finden Sie auf Wallstreet Online.